QIAGEN Extends Support of Cervical Cancer Screening Program for Underprivileged Chinese Women
Collaboration between the leading provider of HPV testing solutions and the Cancer Foundation of China aims to raise awareness for prevention of the world's second most common cancer in women
Beijing, China, March 8, 2010 --- For the third year in a row, QIAGEN and the Cancer Foundation of China are joining hands on International Women's Day to raise awareness about cervical cancer and provide preventative screening. Under terms of the collaboration, QIAGEN has donated its "gold standard" human papillomavirus (HPV) molecular diagnostic test for the screening of several thousand underprivileged women at 30 hospitals across China. The free testing program is part of the larger "3.8 Program" - a nationwide prevention campaign organized by the Cancer Foundation of China and partially sponsored by QIAGEN. HPV is the primary cause of cervical cancer.
"QIAGEN is proud to continue its partnership with the Cancer Foundation of China after the success of the last two year's events," said Dr. Victor Shi, President, Asia Pacific of QIAGEN. "We must continue to increase awareness and work to make HPV testing more accessible to women. QIAGEN is contributing its part through support of the 3.8 Program and other donation activities under our QIAGENcares initiative. We hope that these concerted efforts will help to make cervical cancer a disease of the past in the not-too-distant future."
According to the Cancer Foundation of China, 22 of the hospitals involved in the 2009 cervical cancer screening program reported their result, providing statistics for the testing of 2,383 women. Of those screened, 150 were HPV positive, 18 were found to have mild dysplasia (abnormal cell growth) due to HPV infection (CIN1), 3 had moderate dysplasia (CIN2), and 1 was found to have invasive cervical cancer. All women found to have CIN2 and cancer were referred to local medical centers for further diagnosis and surgery if appropriate.
"The mandate of the Cancer Foundation of China is to improve awareness about cancer and the ways in which it can be prevented and treated. We are particularly passionate about cervical cancer as it is the first cancer that can be prevented with proper screening and treatment methods. Screening with QIAGEN's HPV test allows us to save Chinese lives," said Prof. Qiao Youlin, General Director of the event and Chief of the Department of International Collaboration, Cancer Foundation of China. "Over the last two years we have been able to help thousands of women reduce their risk of developing cervical cancer."
Cervical cancer is the second-most-common cancer affecting women worldwide. Testing women over the age of 30 for the virus that causes the disease significantly improves healthcare professionals' ability to identify women at risk. A landmark eight-year IARC (International Agency for Research on Cancer) study, published in April 2009 in The New England Journal of Medicine, demonstrated that in low-resource settings a single round of HPV testing significantly reduced advanced cervical cancers and deaths, compared with Pap (cytology) testing or visual inspection with acetic acid (VIA). QIAGEN believes that it's digene® HPV Test can help drastically reduce the annual number of cervical cancer deaths in China and around the world.
About HPV and Cervical Cancer:
Worldwide, cervical cancer affects nearly 500,000 women annually and, after breast cancer, is the second most common malignancy found in women. Cervical cancer is caused by "high-risk" types of the human papillomavirus (HPV). It's estimated that 80 percent of women will get an HPV infection at some point in their lives. However, in most cases, the infection goes away or is suppressed by the body without causing problems. It is only infections that persist that can cause abnormal cells to form that may develop into cervical cancer if not detected and treated early.
QIAGEN N.V., a Netherlands holding company, is the leading global provider of sample and assay technologies. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are used to make such isolated bio-molecules visible. QIAGEN has developed and markets more than 500 sample and assay products as well as automated solutions for such consumables. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide. This panel includes the digene HPV Test, which is regarded as a "gold standard" in testing for high-risk types of human papillomavirus (HPV), the primary cause of cervical cancer, as well as a broad suite of solutions for infectious disease testing and companion diagnostics. QIAGEN employs more than 3,500 people in over 30 locations worldwide. Further information about QIAGEN can be found at www.qiagen.com.
About the Cancer Foundation of China:
The Cancer Foundation of China was founded on October 26, 1984. It is a national, non-profit foundation that aims to push forward the development of cancer research, prevention and treatment in China. The scope of the foundation covers various aspects of the cancer research, prevention and treatment, including communications, education and training, prevention and control, fundamental research, application, clinical research, and rehabilitation and analgesia.
QIAGEN SAFE HARBOR STATEMENT
Statements contained in this release that are not historical facts are forward-looking statements, including statements about our products, markets, strategy and operating results. Such statements are based on current expectations that involve risks and uncertainties including, but not limited to, those associated with: management of growth and international operations (including currency fluctuations and logistics), variability of our operating results, commercial development of our markets (including applied testing, clinical and academic research, proteomics, women's health/HPV testing and molecular diagnostics), our relationships with customers, suppliers and strategic partners, competition, changes in technology, fluctuations in demand, regulatory requirements, identifying, developing and producing integrated products differentiated from our competitors' products, market acceptance of our products, and integration of acquired technologies and businesses. For further information, refer to our filings with the SEC, including our latest Form 20-F. Information in this release is as of the date of the release, and we undertake no duty to update this information unless required by law.